Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab IV Re-induction Then Every-4-Week Dosing in Crohn’s Disease with Secondary Loss of Response
KCT0010246Phase 4Recruiting
- Sponsor
- Samsung Bioepis
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of ustekinumab in Crohn's disease, sponsored by Samsung Bioepis. Started Sep 2025; status: recruiting.
02
Drugs
ustekinumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on KCT0010246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0010246.